Herein, in view of the clinical overlap and with regard to lysosomal dysfunction as a shared pathomechanistic feature, we screened for rare NPC1 and NPC2 sequence variants in patients clinically diagnosed with PD, FTLD and PSP, and a cohort of population-based controls. This evidence concerns the gene NPC2 and supranuclear palsy, progressive, 1.